Benzinga | Jan 11, 2022 07:04AM EST

Evogene's Biomica Announces Clearance For First-In-Human Phase I Study Of BMC-128 In Combination With Bristol Myers Squibb's Anti-PD-1 Opdivo

REHOVOT, Israel, Jan. 11, 2022 /PRNewswire/ -- Biomica Ltd., an emerging biopharmaceutical company developing innovative microbiome-based therapeutics and a subsidiary of Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), today announced that the Israeli Ministry of Health (MoH) cleared the company to proceed with its Proof-of-Concept (POC), Phase I clinical trial of Biomica's drug candidate BMC-128 in patients with Non-Small Cell Lung Cancer (NSCLC), Melanoma or Renal Cell Carcinoma (RCC), in combination with immune checkpoint inhibitor (ICI) immunotherapy (an anti-PD-1 agent).